ASURAGEN INCORPORATED

Asuragen Incorporated specializes in the development and manufacturing of in vitro diagnostic reagents, with a focused expertise in quantitative PCR-based molecular assays for clinical and defense applications. Their core capability centers on the design, production, and supply of highly specific nucleic acid-based test kits, including the Quantidex QPCR BCR-ABL IS and Minor Kit reagents used for precise detection of fusion transcripts in hematologic malignancies. This requires advanced molecular biology expertise in primer and probe design, master mix formulation, and stringent quality control for diagnostic accuracy and reproducibility. The company’s technical differentiation lies in its ability to deliver validated, GMP-compliant diagnostic substances that meet the rigorous standards required for clinical decision-making and military medical readiness, particularly in precision oncology applications. Asuragen has demonstrated direct engagement with the Department of Defense, providing critical diagnostic reagents that support operational medical surveillance and personalized treatment protocols for service members. Their work for DoD is narrowly focused on molecular diagnostics for hematologic conditions, indicating a specialized, mission-critical role in military healthcare diagnostics infrastructure. The contractor’s primary industry focus is in in vitro diagnostic substance manufacturing (NAICS 325413), where they operate at the intersection of molecular diagnostics and biopharmaceutical production. Their market positioning is that of a niche supplier of high-complexity, assay-specific reagents rather than broad diagnostic platforms, serving specialized needs in oncology and infectious disease testing. Asuragen Incorporated is a small business entity headquartered in Austin, Texas, with no public government certifications on record. Their geographic presence is centralized in Texas, and they maintain a focused government market position as a specialized supplier of diagnostic reagents to defense and potentially other federal health agencies requiring validated molecular testing solutions.